Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: Implications for drug resistance

Annals of the Rheumatic Diseases

Volumn 68, Issue 7, 2009, Pages 1201-1207

  Kis, E ^a   Nagy, T ^a   Jani, M ^a   Molnar E ^a   Janossy J ^a   Ujhellyi, O ^b   Nemet K ^b   Heredi Szabo K ^a   Krajcsi, P ^a,c  

^a SOLVO BIOTECHNOLOGY   (Hungary)

^b National Blood Transfusion Service   (Hungary)

^c NONE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; BREAST CANCER RESISTANCE PROTEIN; HOE 33342; KO 134; LEFLUNOMIDE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN INHIBITOR; TERIFLUNOMIDE; UNCLASSIFIED DRUG; VANADIC ACID; VESICULAR TRANSPORT PROTEIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; ANILINE DERIVATIVE; ANTIRHEUMATIC AGENT; HYDROXYBUTYRIC ACID; ISOXAZOLE DERIVATIVE; TUMOR PROTEIN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL ASSAY; CELL MEMBRANE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESISTANCE; DRUG TRANSPORT; EMBRYO; ENZYME ACTIVITY; ENZYME ASSAY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; CELL LINE; CELL SURVIVAL; DRUG EFFECT;

ADENOSINE TRIPHOSPHATASES; ANILINE COMPOUNDS; ANTIRHEUMATIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE; CELL SURVIVAL; DRUG RESISTANCE; HUMANS; HYDROXYBUTYRATES; ISOXAZOLES; NEOPLASM PROTEINS;

EID: 67549144268     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2007.086264     Document Type: Article

References (63)

1. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Smith JB, Haynes MK. Rheumatoid arthritis: a molecular understanding. Ann Intern Med 2002;136:908-22.
3. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003;2:473-88.
4. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995;9:619-32.
5. Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 1997;15(Suppl 17):S75-81.
6. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Metaanalysis of treatment termination rates among rheumatoid arthritis patients receiving diseasemodifying anti-rheumatic drugs. Rheumatology (Oxford) 2000;39:975-81.
7. Aletaha D, Smolen JS. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 2002;29:1631-8.
8. Jansen G, Scheper RJ, Dijkmans BAC. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes:an overview. Scand J Rheumatol 2003;32:325-36.
9. Morgan C, Lunt M, Brightwell H, Bradburn P, Fallow W, Lay M, et al. Contribution of patient related differences to multidrug resistance in rheumatoid arthritis. Ann Rheum Dis 2003;62:15-9.
10. van der Heijden J, Dijkmans BAC, Scheper RJ, Jansen G. Drug insight: resistance to methotrexate and other disease-modifying antirheumatic drugs - from bench to bedside. Nat Clin Pract Rheumatol 2007;3:26-34.
11. Glavinas H, Krajcsi P, Cserepes J, Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004;1:27-42.
12. Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
13. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1999;62:385-427.
14. Klein I, Sarkadi B, Váradi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999;1461:237-62.
15. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crit Rev Oncol Hematol 1992;12:243-53.
16. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992;258:1650-4.
17. Deeley RG, Cole SPC. Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 1997;8:193-204.
18. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
19. Bates SE, Robey R, Miyake K, Rao K, Ross DD, Litman TJ. The role of half-transporters in multidrug resistance. Bioenerg Biomembr 2001;33:503-11.
20. Haugland RP. Nucleic acid detection and genomics technology. In: Gregory J, Spenc MTZ, eds. Handbook of fluorescent probes and research products. 9th ed. Eugene, Oregon, USA: Molecular Probes, 2002:280.
21. Ozvegy C, Varadi A, Sarkadi B. Characterization of drug transport, ATP hydrolysis, and nucleotide trapping by the human ABCG2 multidrug transporter. Modulation of substrate specificity by a point mutation. J Biol Chem 2002;277:47980-90.
22. Maillefert JF, Maynadie M, Tebib JG, Aho S, Walker P, Chatard C, et al. Expression of the multidrug resistance glycoprotein 170 in the peripheral blood lymphocytes of rheumatoid arthritis patients. The percentage of lymphocytes expressing glycoprotein 170 is increased in patients treated with prednisolone. Br J Rheumatol 1996;35:430-5.
23. Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann Rheum Dis 2008;67:380-8.
24. Llorente L, Richaud-Patin Y, Díaz-Borjón A, Alvarado de la Barrera C, Jakez-Ocampo J, de la Fuente H, et al. Multidrug resistance-1 (MDR-1) in rheumatic autoimmune disorders. Part I: Increased P-glycoprotein activity in lymphocytes from rheumatoid arthritis patients might influence disease outcome. Joint Bone Spine 2000;67:30-9.
25. Oerlemans R, van der Heijden J, Vink J, Dijkmans BA, Kaspers GJ, Lems WF, et al. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum 2006;54:557-68.
26. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, et al. Development of sulfasalazine resistance in human T cells induces expression of the multidrug resistance transporter ABCG2 (BCRP) and augmented production of TNFalpha. Ann Rheum Dis 2004;63:138- 43.
27. van der Heijden J, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I, et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004;63:131-7.
28. Herrmann ML, Schleyerbach R, Kirschbaum BJ. Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000;47:273-89.
29. Cao WW, Kao PN, Chao AC, Gardner P, Ng J, Morris RE. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995;14(6 Pt 1):1016-30.
30. Fox RI, Herrmann ML, Frangou CG, Wahl GM, Morris RE, Strand V, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999;93:198-208.
31. Kremer JM, Cannon GW. Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 2004;2(5 Suppl 35):S95-100.
32. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
33. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 2005;7:E118-33.
34. Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004;4:31-42.
35. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-59.
36. Ozvegy C, Litman T, Szakacs G, Nagy Z, Bates S, Varadi A, et al. Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun 2001;285:111-7.
37. Zamek-Gliszczynski MJ, Nezasa K, Tian X, Kalvass JC, Patel NJ, Raub TJ, et al. The important role of Bcrp (Abcg2) in the biliary excretion of sulfate and glucuronide metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice. Mol Pharmacol 2006;70:2127-33.
38. Litman T, Brangi M, Hudson E, Fetsch P, Abati A, Ross DD, et al. The multidrugresistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 2000;113(Pt 11):2011-21.
39. Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005;65:2577-82.
40. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000;92:1651-6.
41. Krishnamurthy P, Schuetz JD. The ABC transporter Abcg2/Bcrp: role in hypoxia mediated survival. Biometals 2005;18:349-58.
42. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21.
43. Allen JD, van Loevezijn A, Lakhai JM, van der Valk M, van Tellingen O, Reid G, et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther 2002;1:417-25.
44. Sarkadi B, Price EM, Boucher RC, Germann UA, Scarborough GA. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. J Biol Chem 1992;267:4854-8.
45. Ujhelly O, Ozvegy C, Várady G, Cervenak J, Homolya L, Grez M, et al. Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum Gene Ther 2003;14:403-12.
46. Tucker KA, Lilly MB, Heck L Jr, Rado TA. Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity. Blood 1987;70:372-8.
47. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973;22:3099- 108.
48. Neubig RR, Spedding M, Kenakin T, Christopoulos A. International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification: XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 2003;55:597-606.
49. Dixon M. The graphical determination of Km and Ki. Biochem J 1972;129:197-202.
50. Pál A, Méhn D, Molnár E, Gedey S, Mészáros P, Nagy T, et al. Cholesterol potentiates ABCG2 activity in a heterologous expression system: improved in vitro model to study function of human ABCG2. J Pharmacol Exp Ther 2007;321:1085-94.
51. Glavinas H, Kis E, Pál A, Kovács R, Jani M, Vági E, et al. ABCG2 (breast cancer resistance protein/mitoxantrone resistance-associated protein) ATPase assay: a useful tool to detect drug-transporter interactions. Drug Metab Dispos 2007;35:1533-42.
52. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, et al. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. J Biol Chem 2006;281:23812-23.
53. Van der Heijden JW, Oerlemans R, Tak PP, Smeets TJM, Scheper RJ, Scheffer GL, et al. Expression of the multi-drug resistance protein BCRP in synovial tissue of RA patients: a marker for inflammation or resistance to MTX? Arthritis Rheum 2005;52(Suppl):S540.
54. Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse. Mol Pharm 2006;3:55-61.
55. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-40.
56. Volk EL, Rohde K, Rhee M, McGuire JJ, Doyle LA, Ross DD, et al. Methotrexate cross-resistance in a mitoxantrone-selected multidrug-resistant MCF7 breast cancer cell line is attributable to enhanced energy-dependent drug efflux. Cancer Res 2000;60:3514-21.
57. Breedveld P, Pluim D, Cipriani G, Dahlhaus F, van Eijndhoven MA, de Wolf CJ, et al. The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol 2007;71:240-9.
58. Kremer JM. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999;29:14-26.
59. Dendooven A, Rycke L De, Verhelst X, Mielants H, Veys EM, De Keyser F. Leflunomide and methotrexate combination therapy in daily clinical practice. Ann Rheum Dis 2006;65:833-4.
60. Kiely PDW, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 2002;41:631-7.
61. Kalden JR, Smolen JS, Emery P, van Riel PLCM, Dougados M, Strand CV, et al. Leflunomide in combination therapy. J Rheumatol 2004;31(Suppl 71):25-30.
62. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1322-8.
63. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.